FDA Expands Evolocumab Label for Adults With Increased MACE Risk From Uncontrolled LDL-C
Written by
American Journal Managed Care
Published
0
comments
0
min
Evolocumab is now indicated for adults who don’t have a prior cardiovascular disease diagnosis.